Comparing Kesimpta vs Mavenclad
| Kesimpta (ofatumumab) | Mavenclad (cladribine) |
|
|---|
| Kesimpta (ofatumumab) | Mavenclad (cladribine) |
|
|||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Multiple Sclerosis. Kesimpta may also be used for purposes not listed in this medication guide. |
Prescription only
Mavenclad may be given to people with relapsing forms of MS who have had an inadequate response to, or who are unable to tolerate other medications for MS that have a more favorable safety profile... View more |
||||||||||||||||
| More about Kesimpta (ofatumumab) | More about Mavenclad (cladribine) | ||||||||||||||||
| Ratings & Reviews | |||||||||||||||||
|
Kesimpta has an average rating of 7.0 out of 10 from a total of 81 ratings on Drugs.com. 56% of reviewers reported a positive effect, while 17% reported a negative effect. |
Mavenclad has an average rating of 8.8 out of 10 from a total of 4 ratings on Drugs.com. 75% of reviewers reported a positive effect, while 0% reported a negative effect. |
||||||||||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | |||||||||||||||||
View all Kesimpta side effects |
View all Mavenclad side effects |
||||||||||||||||
| Drug Class | |||||||||||||||||
| Generic Availability | |||||||||||||||||
|
N/A |
|||||||||||||||||
| Pricing and Coupons * Prices are without insurance | |||||||||||||||||
View all Kesimpta prices |
View all Mavenclad prices |
||||||||||||||||
| Dosage Forms | |||||||||||||||||
|
|
||||||||||||||||
| Brand Names | |||||||||||||||||
| Other ofatumumab brands include: Arzerra | Other cladribine brands include: Cladribine Novaplus | ||||||||||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | |||||||||||||||||
|
1476 hours |
6.7 hours |
||||||||||||||||
| CSA Schedule 1 View glossary of CSA terms | |||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||
| Pregnancy Category | |||||||||||||||||
|
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
||||||||||||||||
| Drug Interactions | |||||||||||||||||
|
A total of 182 drugs are known to interact with Kesimpta:
|
A total of 506 drugs are known to interact with Mavenclad:
|
||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | |||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
|
||||||||||||||||
| Disease Interactions | |||||||||||||||||
| First Approval Date | |||||||||||||||||
|
N/A |
March 29, 2019 |
||||||||||||||||
| WADA Class View classifications | |||||||||||||||||
|
N/A |
N/A |
||||||||||||||||
| More Information | |||||||||||||||||
| Patient Resources | |||||||||||||||||
| Professional Resources | |||||||||||||||||
| Related Treatment Guide | |||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.